Combination therapy for a specific type of lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug combination (azacitidine plus standard chemotherapy) for people with a certain genetic subtype of diffuse large B-cell lymphoma (DLBCL) that has a mutation in the TP53 gene. It may offer a more targeted treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You have newly diagnosed DLBCL with a TP53 gene mutation
- You are able to perform daily activities with little or no help (ECOG score 0-2)
- Your heart pumps enough blood (LVEF greater than 45%)
- If you have a history of hepatitis B, it must be inactive and your virus levels must be undetectable before starting the trial
- Your liver and kidneys function adequately, and you are expected to live at least 6 more months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy drugs (R-GemOx) plus an additional drug called azacitidine (AZA) for older adults (60+) with DLBCL that hasn't been treated yet. The goal is to see if adding AZA improves the effectiveness of the standard chemotherapy.
This trial tests if a new drug combination works better than the standard treatment for people with a specific, aggressive form of diffuse large B-cell lymphoma (DLBCL) that shows high levels of two proteins, MYC and BCL2. The study aims to improve outcomes by using genetic information to guide treatment choices.
This trial tests a new combination: zanubrutinib (a targeted pill) plus standard chemotherapy (R-CHOP) for people newly diagnosed with DLBCL whose cancer cells have high p53 protein levels. The goal is to see if adding this drug helps shrink tumors better than chemotherapy alone.
This trial tests a targeted therapy designed to match the specific genetic subtype of DLBCL that has a TP53 mutation. It may offer a more effective treatment option for people whose cancer has this genetic change.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This trial tests a combination of three targeted drugs (polatuzumab vedotin, zanubrutinib, and R-CHP) for people newly diagnosed with a specific subtype of DLBCL called non-GCB. The goal is to see if this powerful mix can work better than standard treatment.
Hear when a new TP53 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.